This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Phase 2, Exploratory, Placebo-Controlled, Multic...
Clinical trial

A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Two Dose Regimens of Aes-103 Given for 28 Days to Subjects with Stable Sickle Cell Disease

Read time: 1 mins
Last updated:3rd May 2013
To evaluate the safety and pharmacokinetic (PK) profile of four times daily (q.i.d.) dosing of 1000 mg of Aes 103 in Cohort A and a second dosing regimen (to be determined) in Cohort B given for up to 28 days in adult subjects with stable sickle cell disease (SCD) compared with subjects receiving placebo.
Category Value
Study start date 2013-05-03

View full details